entertainment -WSS

entertainment

author：entertainment 2025-10-01 04:11:13 - browse：59

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： CommonSpirit Health keeps growing, even as it loses money

hotspot

entertainment

WSS

Changes to biosimilar regulatory framework must prioritize patients

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Lasker Awards 2023: Winners in biomedical research

Emergency workers more likely to restrain Black patients: study

Second xenotransplant done with gene

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

knowledge

entertainment

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Emergency workers more likely to restrain Black patients: study

Drug repurposing or repositioning? The language matters

Lasker Awards 2023: Winners in biomedical research

United colonoscopy coverage change 'may cost lives,' doctors say

Ebola vaccine can save some who are already sick, per new study

ChatGPT in medicine: STAT answers readers' burning questions

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

DIEP, the 'gold standard' of breast reconstruction, is under threat

Latigo launches with $135 million for Vertex

leisure time

Resistance to opioid

Report cites 'urgent' need to recruit more diverse clinical trial participants

Having children helps parents live longer, especially after age 80

Study gives hint on South Asians’ higher risk of cardiovascular disease

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Experts study whether long Covid risk adds up with each reinfection

hotspot

focus

entertainment

explore